Pfizer

CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutics. Established in 2003, the company specializes in small-molecule inhibitors targeting p300, CBP, and specific deubiquitinase enzymes, which play a crucial role in regulating gene expression in cancer cells. Its primary research program addresses prostate cancer, a significant cause of male mortality, by modulating the androgen receptor pathway and potentially overcoming resistance mechanisms found in existing treatments. Additionally, CellCentric's products have applications in treating other cancers, including non-small cell lung cancer, breast cancer, and colon cancer. The company's approach aims to provide targeted therapies for various malignancies, addressing unmet medical needs in the oncology field.

CytoReason is a biotechnology company that specializes in developing a cell-centered computational model of the human body to analyze complex biological data. By collecting proprietary information from pharmaceutical companies, CytoReason simulates human diseases at both the tissue and cellular levels. Its advanced platform utilizes machine learning to reconstruct cellular information from bulk tissue, training an immune-specific engine and integrating multi-omics data. This approach enables pharmaceutical and biotech companies to gain mechanistic insights into the immune system, facilitating the discovery and development of targeted therapies. The company's innovative technology helps shorten clinical trial phases, reduce development costs, and increase the likelihood of successful regulatory approval.

Vivet Therapeutics SAS is a biotechnology company based in Paris, France, focused on the research, development, and commercialization of gene therapy treatments for inherited liver disorders and orphan diseases. Founded in 2016, the company utilizes a liver-tropic adeno-associated virus (AAV) to deliver therapeutic genes directly to hepatocytes, aiming to correct genetic disorders at the source. Vivet is particularly engaged in developing innovative solutions for conditions such as Wilson disease, Progressive Familial Intrahepatic Cholestasis (PFIC), and Citrullinemia Type I (CTLN1). To enhance its gene therapy approaches, Vivet collaborates with the Fundación para la Investigación Médica Aplicada at the Centro de Investigación Médica Aplicada, focusing on optimizing AAV vectors for targeted liver delivery and ensuring long-term expression of therapeutic genes.

Gliknik Inc. is a biopharmaceutical company focused on developing therapies for patients with cancer and immune disorders. Founded in 2007 and based in Baltimore, Maryland, Gliknik's product portfolio includes GL-0817, aimed at preventing the recurrence of squamous cell carcinoma of the oral cavity, and GL-2045, which targets various autoimmune diseases such as immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, and Myasthenia gravis. Additionally, the company develops GB-4542, an anti-CD20 monoclonal antibody therapy. Gliknik employs several innovative platforms, including an Immunomodulator Platform that utilizes off-the-shelf peptide drugs to enhance immune responses against cancer, the Stradomer Platform that creates drugs mimicking the efficacy of human intravenous immunoglobulin, and the Stradobody Platform, which produces compounds akin to monoclonal antibodies for tumor cell targeting. Through these initiatives, Gliknik aims to provide meaningful therapies that alleviate suffering for patients facing these challenging health conditions.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.